Cogent Biosciences to present at Guggenheim Healthcare Innovation Conference and grants stock options to new employees

Cogent Biosciences announced it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026. The company also granted inducement equity awards, including stock options and restricted stock units, to six new employees under Nasdaq rules. These moves highlight Cogent's ongoing efforts to advance its precision therapies for genetically defined diseases, including its lead drug candidate bezuclastinib targeting serious conditions like Systemic Mastocytosis and Gastrointestinal Stromal Tumors. Investors can access a live webcast of the conference and a replay will be available for 30 days.

Cogent Biosciences (COGT) shares are trading at USD 31.98 with a notable 3.46% increase as of Oct 28, 2026 03:11 WIB on Pluang. The company’s market cap stands at $5.36 billion, reflecting solid investor interest ahead of its participation in the Guggenheim Healthcare Innovation Conference. Volume on the platform is 2,205,980, indicating active trading among Pluang users.